TY - JOUR
T1 - Clinical proteomics-driven precision medicine for targeted cancer therapy
T2 - Current overview and future perspectives
AU - Zhou, Li
AU - Wang, Kui
AU - Li, Qifu
AU - Nice, Edouard C.
AU - Zhang, Haiyuan
AU - Huang, Canhua
PY - 2016/3/16
Y1 - 2016/3/16
N2 - Cancer is a common disease that is a leading cause of death worldwide. Currently, early detection and novel therapeutic strategies are urgently needed for more effective management of cancer. Importantly, protein profiling using clinical proteomic strategies, with spectacular sensitivity and precision, offer excellent promise for the identification of potential biomarkers that would direct the development of targeted therapeutic anticancer drugs for precision medicine. In particular, clinical sample sources, including tumor tissues and body fluids (blood, feces, urine and saliva), have been widely investigated using modern high-throughput mass spectrometry-based proteomic approaches combined with bioinformatic analysis, to pursue the possibilities of precision medicine for targeted cancer therapy. Discussed in this review are the current advantages and limitations of clinical proteomics, the available strategies of clinical proteomics for the management of precision medicine, as well as the challenges and future perspectives of clinical proteomics-driven precision medicine for targeted cancer therapy.
AB - Cancer is a common disease that is a leading cause of death worldwide. Currently, early detection and novel therapeutic strategies are urgently needed for more effective management of cancer. Importantly, protein profiling using clinical proteomic strategies, with spectacular sensitivity and precision, offer excellent promise for the identification of potential biomarkers that would direct the development of targeted therapeutic anticancer drugs for precision medicine. In particular, clinical sample sources, including tumor tissues and body fluids (blood, feces, urine and saliva), have been widely investigated using modern high-throughput mass spectrometry-based proteomic approaches combined with bioinformatic analysis, to pursue the possibilities of precision medicine for targeted cancer therapy. Discussed in this review are the current advantages and limitations of clinical proteomics, the available strategies of clinical proteomics for the management of precision medicine, as well as the challenges and future perspectives of clinical proteomics-driven precision medicine for targeted cancer therapy.
KW - clinical proteomics
KW - precision medicine
KW - cancer therapy
KW - mass spectrometry
KW - drug target identification
UR - http://www.ncbi.nlm.nih.gov/pubmed/26923776
U2 - 10.1586/14789450.2016.1159959
DO - 10.1586/14789450.2016.1159959
M3 - Review Article
VL - 13
SP - 367
EP - 381
JO - Expert Review of Proteomics
JF - Expert Review of Proteomics
SN - 1478-9450
IS - 4
ER -
